FLAG方案治疗难治或复发急性髓系白血病26例临床观察  

Clinical Observation of Fludarabine、 Intermediate-dose Ara-C and G-CSF in Treatment for Refractory or Relapsed Acute Myeloid Leukemia（26 Cases）

作　　者：董海林 杨常建 陈晓亮 

机构地区：[1]平顶山煤业集团总医院血液肿瘤科,河南省平顶山467000

出　　处：《中国基层医药》2010年第15期2050-2052,共3页Chinese Journal of Primary Medicine and Pharmacy

摘　　要：目的 研究FLAG方案（氟达拉宾、阿糖胞苷和粒细胞集落刺激因子联合应用）治疗难治/复发急性髓细胞白血病的疗效和不良反应.方法 26例难治或复发性急性髓系白血病（难治15例,复发11例）患者接受FLAG方案治疗,包括氟达拉宾（Flud）30 mg·m-2·d-1,第1～5天;阿糖胞苷（Ara-C）1 000 mg/d,第1～5天;重组人粒细胞刺激因子（G-CSF）300μg/d,第0～5天.疗效评价标准为完全缓解（CR）、部分缓解（PR）、未缓解（NR）.评估其疗效.结果 26例患者中14例达完全缓解（53.8%）,5例部分缓解（19.2%）,总有效率73.1%.该治疗方案毒副作用主要为骨髓抑制、中性粒细胞减少、消化道症状、轻度肝功能异常等.结论 FLAG方案治疗难治或复发AML疗效较好,副作用可以耐受,治疗相关病死率低,是难治或复发性AML首选治疗方案之一.Objective To observe the therapeutic effects and side effects of FLAG regimen（fludarabine, Ara-C, and granulocyte-colony stimulating factor（ C-CSF） for refractory or relapsed acute myeloid leukemia（ AML）. Methods Twenty-six AML were treated with fludarabine plus intermediate-dose Ara-C and G-CSF,of whom 15 cases belonged to refractory and 11 cases belonged to relapsed. Results After two courses of treatment, 14 cases were completely relieved （53. 8% ） and 5 cases were partially relieved （19.2% ）. The overall effective rates was 73.1%. The main side effects were severe myelosuppression and non-hematological toxicity was mild. Conclusion FLAG regimen was very effective for refractory or relapsed acute myeloid leukemia and was well tolerated. The treatment-related mortality rate was low,so it provided a treatment choice for these patients.

关 键 词：白血病 髓样 氟达拉宾 阿糖胞苷 粒细胞集落刺激因子 治疗结果 

分 类 号：R733[医药卫生—肿瘤]